apratastat
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2004 (NCT00095342)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ADAM17INHIBITOR
ADAM17 inhibitor
- Matrix metalloproteinase 13INHIBITOR
Matrix metalloproteinase 13 inhibitor
Inhibition of MMP-13 is relevant to the indication osteoarthritis (PMID: 23298463).
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO- Mol. weight
- 414.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL206815 ↗
Also known as
- 4-((4-(2-butynyloxy)phenyl)sulfonyl)-n-hydroxy-2,2-dimethyl-(3s)thiomorpholinecarboxamide
- apratastat
- apratastat
- tmi 005
- tmi-005
- tmi-005
- tmi-005
- tmi-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00095342 | Phase 2 | Nov 2, 2004 | Pfizer, Wyeth |
Showing 1 of 1 trials
Page 1 / 1